Instil Bio Q3 net loss $67.4M; restructuring charges $46.3M; cash runway beyond 2026

Instil Bio, Inc.

2023-Q3 EPS reported -$1.10

Net loss $67.4M ($0.52 per share) vs $56.2M ($0.43) in Q3 2022.
Cash, equivalents, restricted cash and marketable securities $184.5M, down from $260.9M at Dec 31, 2022.
Restructuring and impairment charges of $46.3M in Q3 2023; none in prior year.
R&D expenses dropped to $8.5M from $39.7M reflecting pipeline reprioritization.
Cash runway expected beyond 2026; ITIL-306 Phase 1 data in NSCLC anticipated in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Instil Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss $(67,432) (in thousands), EPS Net loss per share, basic and diluted $(0.52).

Period: the quarter ended September 30, 2023
Net income: Net loss $(67,432) (in thousands)
EPS: Net loss per share, basic and diluted $(0.52)
Result: reported results

Exact text from the filing

On November 13, 2023 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-23-000090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.